Skip to main content
. 2009 Sep 5;19(5):244–250. doi: 10.2188/jea.JE20081035

Table 4. Effect of combined ADH1B and ALDH2 genotype on the risk of female breast cancer.

  ADH1B (*2:rapid/*2:rapid) ADH1B (*1:slow/*2:rapid) ADH1B (*1:slow/*1:slow)
Cases
/Controls		 OR
(95% CI)		 P Cases
/Controls		 OR
(95% CI)		 P Cases
/Controls		 OR
(95% CI)		 P
ALDH2 (*1:active/*1:active) 132/278     77/148     9/24    
​ OR-1a (95% CI)   1 (ref.)     1.1 (0.78–1.55) 0.589   0.79 (0.36–1.75) 0.559
​ OR-2b (95% CI)   1 (ref.)     1.13 (0.8–1.61) 0.483   0.84 (0.37–1.89) 0.675
                   
ALDH2 (*1:active/*2:null) 101/207     80/131     15/20    
​ OR-1a (95% CI)   1.03 (0.75–1.41) 0.867   1.29 (0.91–1.82) 0.155   1.58 (0.78–3.19) 0.201
​ OR-2b (95% CI)   0.98 (0.71–1.37) 0.929   1.26 (0.88–1.82) 0.209   1.65 (0.7–1.95) 0.173
                   
ALDH2 (*2:null/*2:null) 32/53     5/37     1/3    
​ OR-1a (95% CI)   1.27 (0.78–2.06) 0.342   0.28 (0.11–0.73) 0.009   0.65 (0.07–6.33) 0.711
​ OR-2b (95% CI)   1.16 (0.7–1.95) 0.56   0.26 (0.1–0.69) 0.007   0.61 (0.06–6.07) 0.675

aLogistic regression model controlling for matching factors only.

bLogistic regression model controlling for matching factors plus alcohol consumption, smoking status, body-mass index, regular exercise, family history of breast cancer, age at menarche, parity, hormone-replacement therapy and mode of referral to hospital.

There were 4 cases and 11 controls with unknown ADH1B and/or ALDH2 genotypes.